Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Recombinant Dna Technology Market Set To Witness Significant Growth By 2024-2031: Sanofi , Pfizer, Inc., Amgen, Inc. Recombinant Dna technology market is expected to reach USD 327.63 Bn by 2031, ...

Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

The U.S. Patent Office has published updated examination guidelines regarding the enablement requirement in view of the ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...

IMTOZ trial findings and subsequent approval of Isa-VRd regimen for transplant-ineligible myeloma suggested the combo as a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Which CEO drank out of my colleague Matt Herper’s ...

A US appeals court has ruled that Regeneron and Sanofi’s Praluent can stay on the market while they appeal a patent case from rival Amgen that blocked them from selling it. Last month ...